The combination of circumstances confronting the sector must be unprecedented - 20 per cent growth in spending on the PBS, but actually no growth, a policy requirement to offset the cost of all new listings driven by impossible fiscal circumstances, with an existing $2 billion hole in health spending, against the backdrop of the Turnbull government's innovation agenda and commitment to fund new medicines. What does it all mean?
Latest Video
New Stories
-
Illumina taps medtech leader to head Australia and New Zealand operations
July 8, 2026 - - Latest News -
PYC Therapeutics names Thomas Ulmer as new chief financial officer
July 8, 2026 - - Australian Biotech -
In a perfect world, the minister would not be in this position, and he might question the timeline
July 8, 2026 - - Latest News -
Aegros completes Australia’s second large scale plasma fractionation plant
July 8, 2026 - - Latest News -
'But I've said it's really important that these two drugs stay on the PBS'
July 7, 2026 - - Latest News -
Just another attempt to create a new excuse to avoid a meaningful discussion about change
July 7, 2026 - - Latest News -
Australia must keep development manufacturing and jobs here to secure health and economic benefits
July 7, 2026 - - Latest News

